| Exercise Therapy in Radiation Therapy (NCT03905356) | Milton S. Hershey Medical Center | 2020-02-12 |
| First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector (NCT04053283) | Akamis Bio | 2020-01-23 |
| S1916 Digital Medicine Program for Pain Control in Cancer Patients (NCT04194528) | SWOG Cancer Research Network | 2020-01-22 |
| Pembrolizumab in Biliary Tract Cancer (NCT03260712) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-01-07 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a) (NCT04257162) | SOLTI Breast Cancer Research Group | 2019-12-13 |
| pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer (NCT04090528) | University of Wisconsin, Madison | 2019-10-21 |
| Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry (NCT04085029) | Duke University | 2019-09-26 |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (NCT03954067) | Astellas Pharma Global Development, Inc. | 2019-09-03 |
| Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC) (NCT03868046) | Hospital Universitario Araba | 2019-08-25 |
| An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NCT03864575) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2019-08-15 |
| Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT03909334) | Xiuning Le | 2019-07-25 |
| QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (NCT04050709) | ImmunityBio, Inc. | 2019-07-18 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (NCT03941262) | NKGen Biotech, Inc. | 2019-07-15 |
| Efficacy of Point Of Service Testing in MBC (NCT03983577) | University of Kansas Medical Center | 2019-06-11 |
| Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients (NCT04714203) | Weprom | 2019-06-01 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
| Crizotinib in ALK Rearranged Non-small-cell Lung Cancer (NCT04317651) | Fondazione Ricerca Traslazionale | 2019-05-16 |
| Predicting Disease Progression and/or Recurrence in Cancer (NCT04776837) | Massachusetts General Hospital | 2019-05-15 |
| The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment (NCT03873103) | The Belgian Society of Medical Oncology | 2019-03-31 |
| First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (NCT03852511) | Akamis Bio | 2019-02-19 |
| ImmunoPET With an Anti-CD8 Imaging Agent (NCT04029181) | University Medical Center Groningen | 2019-02-14 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (NCT03785249) | Mirati Therapeutics Inc. | 2019-01-15 |
| Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. (NCT03869762) | Cancer Trials Ireland | 2019-01-09 |
| An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer (NCT03794635) | Memorial Sloan Kettering Cancer Center | 2018-12-20 |
| Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (NCT03714958) | Centre Leon Berard | 2018-12-20 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (NCT03570619) | University of Michigan Rogel Cancer Center | 2018-12-14 |
| Feasibility, Acceptability and Preliminary Effects of the Spiritual Care Assessment and Intervention (NCT03823313) | Indiana University | 2018-12-10 |
| Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy (NCT03712566) | University Health Network, Toronto | 2018-11-06 |
| Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT03691714) | Trisha Wise-Draper | 2018-10-23 |
| A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors (NCT03693014) | Memorial Sloan Kettering Cancer Center | 2018-10-01 |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer (NCT03475004) | University of Colorado, Denver | 2018-09-17 |
| Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden (NCT03671720) | Capital Medical University | 2018-09-11 |
| Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood (NCT03058809) | Viatar LLC | 2018-09-01 |
| A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy (NCT03391479) | University Health Network, Toronto | 2018-08-15 |
| Reducing Disparities in the Quality of Advance Care Planning for Older Adults (NCT03516994) | Duke University | 2018-08-01 |
| Herzuma-capecitabine/Cisplatin for Gastric Cancer (NCT03588533) | Sung Yong Oh | 2018-06-10 |
| Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma (NCT03585673) | Sung Yong Oh | 2018-06-01 |
| Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03489343) | Symphogen A/S | 2018-05-24 |
| Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors (NCT03510104) | Meryx, Inc. | 2018-05-22 |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (NCT03569241) | University Hospital, Ghent | 2018-04-27 |
| Biomarkers of Immune-Related Toxicity (NCT03409016) | University of Colorado, Denver | 2018-04-18 |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies (NCT03440437) | invoX Pharma Limited | 2018-04-16 |
| Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases (NCT03757858) | Capital Medical University | 2018-03-01 |
| RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. (NCT03375437) | Centre Leon Berard | 2018-02-15 |
| Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (NCT03356223) | Centre Leon Berard | 2018-02-05 |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (NCT03392428) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2018-01-29 |
| A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126) | Asana BioSciences | 2018-01-19 |
| A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers (NCT04710290) | E-DA Hospital | 2018-01-04 |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (NCT03277352) | Incyte Biosciences International Sàrl | 2017-11-21 |
| Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03311412) | Symphogen A/S | 2017-11-20 |
| Electronic Patient Reporting of Symptoms During Cancer Treatment (NCT03249090) | Alliance Foundation Trials, LLC. | 2017-10-30 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors (NCT03295942) | OncoMed Pharmaceuticals, Inc. | 2017-09-12 |
| Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor (NCT03721055) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2017-08-21 |
| A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers (NCT02919696) | Eli Lilly and Company | 2017-08-07 |
| Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO) (NCT02857400) | Institut Claudius Regaud | 2017-07-21 |
| The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours (NCT03863106) | Hospices Civils de Lyon | 2017-07-15 |
| Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (NCT03219775) | AIO-Studien-gGmbH | 2017-07-06 |
| A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates (NCT03486431) | Cancer Research Antwerp | 2017-07-05 |
| Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma (NCT03024437) | Roberto Pili | 2017-06-29 |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (NCT03009058) | Immodulon Therapeutics Ltd | 2017-05-31 |
| Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool (NCT04143230) | A.O.U. Città della Salute e della Scienza | 2017-05-23 |
| Mindfulness to Enhance Quality of Life and Support Advance Care Planning (NCT03257007) | Indiana University | 2017-05-09 |
| Predictive Nomogram of CRPC (NCT03177551) | Tianjin Medical University Second Hospital | 2017-05-04 |
| A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03119428) | OncoMed Pharmaceuticals, Inc. | 2017-05-02 |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies (NCT03126110) | Incyte Biosciences International Sàrl | 2017-04-25 |
| Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition (NCT03453892) | University of Erlangen-Nürnberg Medical School | 2017-04-01 |
| Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck (NCT03132038) | UNICANCER | 2017-03-24 |
| Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) (NCT02959437) | Incyte Corporation | 2017-02-27 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer (NCT03027284) | Eli Lilly and Company | 2017-02-03 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) (NCT03013218) | ALX Oncology Inc. | 2017-02-03 |
| Mobile Health Technology for Palliative Care Patients (NCT03038841) | University of Zurich | 2017-02-01 |
| Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology (NCT03012139) | Mayo Clinic | 2017-01-01 |
| Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor (NCT03299452) | Haining Health-Coming Biotech Co., Ltd. | 2017-01-01 |
| A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors (NCT02923349) | Incyte Biosciences International Sàrl | 2016-10-31 |
| Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics (NCT02828462) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-10-24 |
| Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (NCT02903914) | Incyte Corporation | 2016-09-14 |
| Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease (NCT02843165) | University of California, San Diego | 2016-09-02 |
| RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) (NCT02801097) | EpicentRx, Inc. | 2016-08-30 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780) | Eli Lilly and Company | 2016-08-10 |
| Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer (NCT03936205) | Hotel Dieu de France Hospital | 2016-08-01 |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors (NCT02697591) | Incyte Biosciences International Sàrl | 2016-06-20 |
| Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (NCT02777710) | Centre Leon Berard | 2016-06-01 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (NCT02711553) | Eli Lilly and Company | 2016-05-19 |
| Treat Primary and Metastatic Liver Tumors (NCT05240040) | Methodist Health System | 2016-04-26 |
| Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer (NCT02646228) | Samsung Medical Center | 2016-02-04 |
| Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer (NCT02293954) | City of Hope Medical Center | 2015-11-11 |
| Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic. (NCT02593578) | Samsung Medical Center | 2015-10-28 |
| A Study of LY3076226 in Participants With Advanced or Metastatic Cancer (NCT02529553) | Eli Lilly and Company | 2015-09-01 |
| Comparing Palliative Radiotherapy With or Without Carboplatin (NCT03637335) | Institut Cancerologie de l'Ouest | 2015-08-17 |
| A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NCT02442531) | Cristal Therapeutics | 2015-08-01 |
| Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy (NCT02412462) | Alethia Biotherapeutics | 2015-04-01 |
| Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model (NCT02141152) | Samsung Medical Center | 2015-02-01 |
| CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. (NCT03381326) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2014-12-15 |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (NCT03176485) | University of Arizona | 2014-10-17 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (NCT02265510) | Incyte Corporation | 2014-09-10 |